乙酰肝素酶
癌症研究
硫酸乙酰肝素
肉瘤
蛋白多糖
生物
肿瘤微环境
造血
细胞
免疫学
医学
细胞生物学
病理
细胞外基质
干细胞
肿瘤细胞
生物化学
作者
Giuliana Cassinelli,Nadia Zaffaroni,Cinzia Lanzi
出处
期刊:Cancer Letters
[Elsevier]
日期:2016-11-01
卷期号:382 (2): 245-254
被引量:23
标识
DOI:10.1016/j.canlet.2016.09.004
摘要
Heparanase, the only known mammalian endoglycosidase degrading heparan sulfate (HS) chains of HS proteoglycans (HSPG), is a highly versatile protein affecting multiple events in tumor cells and their microenvironment. In several malignancies, deregulation of the heparanase/HSPG system has been implicated in tumor progression, hence representing a valuable therapeutic target. Currently, multiple agents interfering with the heparanase/HSPG axis are under clinical investigation. Sarcomas are characterized by a high biomolecular complexity and multiple levels of interconnection with microenvironment sustaining their growth and progression. The clinical management of advanced diseases remains a challenge. In several sarcoma subtypes, high levels of heparanase expression have been correlated with poor prognosis associated factors. On the other hand, expression of cell surface-associated HSPGs (i.e. glypicans and syndecans) has been found altered in specific sarcoma subtypes. Recent studies provided the preclinical proof-of-principle of the role of the heparanase/HSPG axis as therapeutic target in various sarcoma subtypes. Although currently there are no clinical trials evaluating agents targeting heparanase and/or HSPGs in sarcomas, we here provide arguments for this strategy as potentially able to implement the therapeutic options for sarcoma patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI